19 November 2015 - NICE will this morning issue a Final Appraisal Determination recommending the use of Bayer’s Xofigo on the National Health Service to treat certain patients with prostate cancer, but only in the post-chemotherapy setting.

For more details, go to: http://www.pharmatimes.com/Article/15-11-19/NICE_OK_s_restricted_use_of_Bayer_s_prostate_cancer_drug.aspx?